Indication

ENSPRYNG (satralizumab-mwge) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are AQP4-IgG(+). 1

ENSPRYNG PROVEN IN 2 CLINICAL TRIALS

Alone and with concurrent immunosuppressive therapy 1

ENSPRYNG SAFETY

Observed for a median of ~2 and ~3 years in 2 clinical trials 1

SUBCUTANEOUS INJECTION

Intended for self-administration after proper guidance 1